Skip to main content
. 2023 Feb 19;15(4):1320. doi: 10.3390/cancers15041320

Figure 4.

Figure 4

Diagram of the p85/p110 (PI3K) signaling pathway. PI3K leads to the formation of the second messenger, PIP3. PDK1 and AKT are then recruited to the membrane. PDK1 and mTORC2 phosphorylate AKT, fully activating it. AKT then phosphorylates TSC, which is a negative regulator of mTORC1. Alpelisib is a PI3K inhibitor, and Everolimus is an mTOR inhibitor. Created with BioRender.com.